Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG (TiCAB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01755520|
Recruitment Status : Terminated (DSMB Interim Analyses)
First Posted : December 24, 2012
Last Update Posted : August 2, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
The primary efficiacy MACCE-endpoint is the composite of cardiovascular death, myocardial infarction, recurent revascularisation, and stroke at twelve month after coronary artery bypass operation.
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Stable Angina Acute Coronary Syndrome||Drug: Ticagrelor Drug: Aspirin Drug: Placebo - Ticagrelor Drug: Placebo - Aspirin||Phase 3|
For stable patients who underwent coronary bypass operation, Aspirin alone currently represents the gold standard of antiplatelet treatment.
The CABG substudy of the PLATO-trial (http://www.nejm.org/doi/full/10.1056/NEJMoa0904327) comprising more than 1200 patients has convincingly shown a high significant reduction of cardiovascular and all-cause mortality for patients recieving Aspirin and Ticagrelor as compared to those subjects randomized to Aspirin plus Clopidogrel. Moreover the results of the PLATO CABG substudy showed that benefits of Ticagrelor increase with decreasing Aspirin doses. Therefore Ticagrelor monotherapy (2x 90mg/day) appears to offer the best balance of safety with anticipated improved efficacy over Aspirin (1x 100mg/day) alone, but until now there are no further data available to support this hypothesis.
Hence this study (TiCAB) is assigned as a pivotal efficacy and safety study of Ticagrelor in patients undergoing coronary artery bypass operation and to test the hypothesis that ticagrelor is superior to Aspirin for the prevention of major cardio- and cerebrovascular events (MACCE) in this patient population.
The TiCAB trial is designed as a randomized, double-blind, double-dummy, parallel group, phase III, multicenter study, comparing the efficacy and safety of Ticagrelor 90mg administered twice daily with Aspirin 100mg once daily, for the prevention of MACCE within the first year after CABG operation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1893 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG|
|Study Start Date :||April 24, 2013|
|Actual Primary Completion Date :||May 19, 2018|
|Actual Study Completion Date :||May 19, 2018|
Intervention: Drug: Ticagrelor verum + Aspirin placebo
90mg twice daily dose
Other Name: Brilique
Drug: Placebo - Aspirin
Other Name: Placebo
Active Comparator: Aspirin
Intervention: Drug: Aspirin verum + Ticagrelor placebo
Aspirin 100mg once daily
Other Name: ASS
Drug: Placebo - Ticagrelor
Other Name: Placebo
- MACCE [ Time Frame: at 12 months after coronary artery bypass surgery ]Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke
- Cardiovascular death [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Major bleeding events [ Time Frame: within 12 months after coronary arerty bypass surgery ]Incidence of major bleeding events
- All cause death [ Time Frame: at 12 months after coronary artery bypass surgery ]All cause death
- Myocardial Infarction [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Target Lesion Revascularization [ Time Frame: at 12 months after coronary artery bypass surgery ]
- Stroke [ Time Frame: at 12 months after coronary artery bypass surgery ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients 18 years of age or older
- Informed, written consent by the patient
Indication for CABG surgery:
- coronary three vessel disease, or
- left main stenosis, or
- two vessel disease with impaired left ventricular function (<50%)
- Cardiogenic shock, haemodynamic instability
- Indication for oral anticoagulation or dual antiplatelet therapy that can not be stopped after CABG
- Need for concomitant non-coronary surgery (e.g. valve replacement)
- Intolerance of or Allergy to Ticagrelor or ASA or any of their ingredients
- History of bleeding diathesis within three months prior presentation
- History of significant gastrointestinal bleeding within six months prior presentation
- History of intracranial hemorrhage
- History of moderate to severe liver impairment (Child Pugh B or C)
- Chronic renal insufficiency requiring dialysis
- Patient with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope)
- Known, clinically important thrombocytopenia (i.e. <100.000/µl)
- Known, clinically important anaemia (i.e. <10mg/dl)
- Participation in another investigational drug or device study in the last 30 days
- Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required); in women with childbearing potential a pregnancy test is mandatory
Concomitant oral or intravenous therapy (see examples below) with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers which cannot be stopped for the course of the study
- Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, over 1 litre daily of grapefruit juice.
- Substrates with narrow therapeutic index: cyclosporine, quinidine.
- Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.
- Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow-up, active cancer
- Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)
- Previous enrollment or randomization of treatment in the present study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755520
|Study Chair:||Heribert Schunkert, MD||Deutsches Herzzentrum Munich Germany|
|Responsible Party:||Deutsches Herzzentrum Muenchen|
|Other Study ID Numbers:||
GE IDE No. D00112
2012-003630-16 ( EudraCT Number )
|First Posted:||December 24, 2012 Key Record Dates|
|Last Update Posted:||August 2, 2018|
|Last Verified:||August 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Coronary Artery Disease
Acute Coronary Syndrome
Arterial Occlusive Diseases
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors